Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$12.27M$12.27M+10.3% vs Q1 2021 Net Income-$13.22M-$13.22MN/M vs Q1 2021 EPS Diluted-$0.32-$0.32N/M vs Q1 2021 Operating Income-$9,738,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
Free Cash Flowderived-$14,586,000N/M Margins · derivedOperating margin-79.4%−2.7 pt vs Q1 2021
Net margin-107.7%+24.2 pt vs Q1 2021
ended Mar 31, 2022 · filed May 4, 2022 · 34 d after period end